×

TESARO Announces Six Abstracts to be Presented at the 2015 Multinational Association of Supportive Care in Cancer Annual Meeting

WALTHAM, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of six abstracts at the 2015 Multinational Association of Supportive Care in Cancer (MASCC/ISOO) Annual Meeting, June 25 to 27, 2015, in Copenhagen.

Presentation Details:

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly- or moderately emetogenic chemotherapy (HEC; MEC)
Abstract: 11-03-O, Oral Presentation, Friday, June 26, 2015 from 5:45 PM to 7:15 PM

Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC)
Abstract: 11-38-P, Poster Presentation, Friday, June 26, 2015

Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non-anthracycline/cyclophosphamide (A/C) moderately emetogenic therapy (MEC)
Abstract: 11-39-P, Poster Presentation, Friday, June 26, 2015

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) using anthracycline-cyclophosphamide (AC)-based chemotherapy
Abstract: 11-11-P, Poster Presentation, Friday, June 26, 2015

Pharmacokinetics of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy volunteers
Abstract: 11-20-P, Poster Presentation, Friday, June 26, 2015

Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics of rolapitant, a novel NK-1 receptor antagonist
Abstract: 11-07-P, Poster Presentation, Friday, June 26, 2015

Rolapitant is an investigational product candidate that has not been approved by any regulatory agency.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

CONTACT: Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or jdavis@tesarobio.com

Source:TESARO, Inc.